[go: up one dir, main page]

PE20011046A1 - Composiciones y procedimientos para el tratamiento de afecciones que responden a estrogenos - Google Patents

Composiciones y procedimientos para el tratamiento de afecciones que responden a estrogenos

Info

Publication number
PE20011046A1
PE20011046A1 PE2001000019A PE2001000019A PE20011046A1 PE 20011046 A1 PE20011046 A1 PE 20011046A1 PE 2001000019 A PE2001000019 A PE 2001000019A PE 2001000019 A PE2001000019 A PE 2001000019A PE 20011046 A1 PE20011046 A1 PE 20011046A1
Authority
PE
Peru
Prior art keywords
phenyl
alkyl
etoxy
naphthalen
tetrahydro
Prior art date
Application number
PE2001000019A
Other languages
English (en)
Inventor
Wesley Warren Day
David Duane Thompson
Robert Louis Rosati
Andrew George Lee
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20011046A1 publication Critical patent/PE20011046A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO AGONISTA/ANTAGONISTA DE ESTROGENOS DE FORMULA I DONDE A ES CH2, NR; B, D Y E SON CH, N; Y ES FENILO, NAFTILO, CICLOALQUILO C3-C8, CICLOALQUENILO C3-C8, HETEROCICLO, ENTRE OTROS; Z1 ES -(CH2)pW(CH2)q-, -O(CH2)pCR5R6-, -O(CH2)pW(CH2)q-, -OCHR2CHR3-, ENTRE OTROS; G ES -NR7R8, GRUPO a; n ES 0-2, m ES 1-3, Z2 ES NH, O, S, CH2, ENTRE OTROS; W ES CH2, -CH=CH-, O, NR2, S(O)n, CO, ENTRE OTROS; R ES H, ALQUILO C1-C6; R2 Y R3 SON H, ALQUILO C1-C4; R4 ES H, HALOGENO, ALQUILO C1-C6, ALCOXI C1-C4 ENTRE OTROS; R5 Y R6 SON ALQUILO C1-C8 O JUNTOS FORMAN UN ANILLO CARBOCICLICO C3-C10; R7 Y R8 SON FENILO CARBOCICLICO C3-C10, HETEROCICLICO C3-C10, H, ALQUILO C1-C6, ENTRE OTROS; UN ANILLO FORMADO POR R7 Y R8 PUEDE ESTAR OPCIONALMENTE CONDENSADO CON UN ANILLO FENILO; e ES 0-2; m ES 1-3; n ES 0-2; p ES 0-3; q ES 0-3. LOS COMPUESTOS AGONISTA/ANTAGONISTA DE ESTROGENOS SE SELECCIONA DEL GRUPO CIS-6-(4-FLUORO-FENIL)-5-[4-(2-PIPERIDIN-1-IL-ETOXI)-FENIL]-5,6,7,8-TETRAHIDRO-NAFTALEN-2-OL, (-)-CIS-6-FENIL-5-(4-(2-PIRROLIDIN-1-IL-ETOXI)-FENIL]-5,6,7,8-TETRAHIDRO-NAFTALEN-2-OL, CIS-6-FENIL-5-(4-(2-PIRROLIDIN-1-IL-ETOXI)-FENIL]-5,6,7,8-TETRAHIDRO-NAFTALEN-2-OL, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA DONDE EL AGONISTA/ANTAGONISTA DE ESTROGENOS ESTA EN LA FORMA DE UNA SAL D-TARTRATO; LACOMPOSICION ES UTIL PARA EL TRATAMIENTO DE ARTRITIS REUMATOIDE, CANCER DE COLON
PE2001000019A 2000-01-12 2001-01-10 Composiciones y procedimientos para el tratamiento de afecciones que responden a estrogenos PE20011046A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17575200P 2000-01-12 2000-01-12

Publications (1)

Publication Number Publication Date
PE20011046A1 true PE20011046A1 (es) 2001-10-19

Family

ID=22641493

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000019A PE20011046A1 (es) 2000-01-12 2001-01-10 Composiciones y procedimientos para el tratamiento de afecciones que responden a estrogenos

Country Status (20)

Country Link
US (2) US6632834B2 (es)
EP (1) EP1120114B1 (es)
JP (1) JP2001213776A (es)
KR (1) KR100402563B1 (es)
AT (1) ATE345794T1 (es)
AU (1) AU780142B2 (es)
CA (3) CA2475413A1 (es)
CO (1) CO5271709A1 (es)
CY (1) CY1106272T1 (es)
DE (1) DE60124600T2 (es)
DK (1) DK1120114T3 (es)
ES (1) ES2274853T3 (es)
HU (1) HUP0100120A3 (es)
IL (1) IL140802A (es)
MY (1) MY133571A (es)
NZ (1) NZ509321A (es)
PE (1) PE20011046A1 (es)
PT (1) PT1120114E (es)
TW (1) TWI246918B (es)
ZA (1) ZA200100177B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517532B1 (en) 1997-05-15 2003-02-11 Palomar Medical Technologies, Inc. Light energy delivery head
US6916495B2 (en) * 1999-02-24 2005-07-12 Allan Taylor Preparation for regulating lower bowel function
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
US20080306471A1 (en) * 2000-12-28 2008-12-11 Palomar Medical Technologies, Inc. Methods and devices for fractional ablation of tissue
DE60124585T2 (de) * 2000-12-28 2007-10-04 Palomar Medical Technologies, Inc., Burlington Apparat zur therapeutischen elektromagnetischen Strahlentherapie von der Haut
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
AU2003245573A1 (en) 2002-06-19 2004-01-06 Palomar Medical Technologies, Inc. Method and apparatus for treatment of cutaneous and subcutaneous conditions
CA2503549C (en) * 2002-10-23 2012-07-10 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
CA2513432A1 (en) * 2003-01-22 2004-08-05 Pfizer Products Inc. Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
WO2005070403A1 (en) * 2004-01-23 2005-08-04 Creighton University Anti-estrogens and methods of use
US20060020035A1 (en) * 2004-03-11 2006-01-26 Oregon Health & Science University Bone marrow protection with N-acetyl-L-cysteine
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
MX2007000481A (es) 2004-07-14 2007-03-29 Ptc Therapeutics Inc Metodos para tratar hepatitis c.
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
US7856985B2 (en) 2005-04-22 2010-12-28 Cynosure, Inc. Method of treatment body tissue using a non-uniform laser beam
US8071287B2 (en) 2005-04-22 2011-12-06 Liggett Stephen B Pharmaceutical and therapeutic applications relating to a type 9 adenylyl cyclase Polymorphism in asthma and reversible bronchial obstruction
WO2007035444A2 (en) * 2005-09-15 2007-03-29 Palomar Medical Technologies, Inc. Skin optical characterization device
US7586957B2 (en) 2006-08-02 2009-09-08 Cynosure, Inc Picosecond laser apparatus and methods for its operation and use
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
CA2676066C (en) * 2007-01-22 2016-06-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
TW201043595A (en) * 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
US9919168B2 (en) 2009-07-23 2018-03-20 Palomar Medical Technologies, Inc. Method for improvement of cellulite appearance
AU2011264858B2 (en) 2010-06-10 2016-04-21 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CA3065694A1 (en) * 2010-11-10 2012-05-18 Inregen Methods of forming injectable formulations for providing regenerative effects to an organ such as a kidney
BR112014014124A2 (pt) 2011-12-14 2017-08-22 Seragon Pharmaceutical Inc Moduladores do receptor de estrogênio fluorados e usos dos mesmos
EP2839552A4 (en) 2012-04-18 2015-12-30 Cynosure Inc PICOSCOPE LASER DEVICE AND METHOD FOR THE TREATMENT OF TARGET FABRICS THEREWITH
WO2014145707A2 (en) 2013-03-15 2014-09-18 Cynosure, Inc. Picosecond optical radiation systems and methods of use
BR122023020677A2 (pt) 2015-10-01 2023-12-12 Olema Pharmaceuticals, Inc. Compostos de tetra-hidro-1h-pirido[3,4-b]indol, composições compreendendo os referidos compostos e usos dos mesmos
BR112018011607B1 (pt) 2015-12-09 2024-01-30 The Board Of Trustees Of The University Of Illinois Composto, composição farmacêutica, uso de um composto ou de uma composição farmacêutica, processo para preparação de um produto farmacêutico
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109789143A (zh) 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
EA201991622A1 (ru) 2017-01-06 2020-01-23 Г1 Терапьютикс, Инк. Комплексная терапия для лечения рака
CN115737636B (zh) * 2017-01-10 2024-08-27 浙江嘉驰医药开发有限公司 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
KR102659211B1 (ko) 2017-06-29 2024-04-18 쥐원 쎄라퓨틱스, 인크. G1t38의 형체 형태 및 그의 제조 방법
CN112042066A (zh) 2018-02-26 2020-12-04 赛诺秀股份有限公司 调q倾腔亚纳秒激光器
CN113453679B (zh) 2018-12-20 2025-07-08 C4医药公司 靶向蛋白降解
WO2021007146A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
AU2020405237A1 (en) 2019-12-20 2022-07-07 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of EGFR
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
EP4192458A4 (en) 2020-08-05 2024-09-04 C4 Therapeutics, Inc. COMPOUNDS FOR TARGETED DEGRADATION OF RET
EP4565585A1 (en) 2022-08-03 2025-06-11 Bristol-Myers Squibb Company Compounds for modulating ret protein
EP4611901A1 (en) 2022-11-04 2025-09-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
KR20250116017A (ko) 2022-11-04 2025-07-31 브리스톨-마이어스 스큅 컴퍼니 Ret-ldd 단백질 억제제
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
GB2273873A (en) * 1992-12-23 1994-07-06 Univ Sheffield Treatment of psoriasis
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5441986A (en) 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
FR2745182B1 (fr) 1996-02-22 1998-06-19 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques contenant un extrait de solanum lycocarpum
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
TW403736B (en) 1997-02-21 2000-09-01 Akzo Nobel Nv Steroid compounds having contraceptive and anti-osteoporosis activity
HUP0002852A3 (en) 1997-08-15 2001-11-28 Univ Durham A method of preventing or treating estrogen-dependent diseases and disorders using triphenil-ethylene derivatives
CO5170459A1 (es) * 1999-06-01 2002-06-27 Pfizer Prod Inc Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos
ATE289300T1 (de) * 1999-12-30 2005-03-15 Signal Pharm Inc Verbindungen und verfahren zur modulation von estrogen rezeptoren
AU2001271782A1 (en) * 2000-07-06 2002-01-21 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts

Also Published As

Publication number Publication date
ES2274853T3 (es) 2007-06-01
DE60124600D1 (de) 2007-01-04
ATE345794T1 (de) 2006-12-15
CA2475393A1 (en) 2001-07-12
US20010041718A1 (en) 2001-11-15
EP1120114B1 (en) 2006-11-22
CA2475413A1 (en) 2001-07-12
PT1120114E (pt) 2007-01-31
CA2331053C (en) 2005-10-25
DE60124600T2 (de) 2007-04-05
HUP0100120A3 (en) 2004-06-28
DK1120114T3 (da) 2007-02-05
KR100402563B1 (ko) 2003-10-17
NZ509321A (en) 2002-10-25
AU1367601A (en) 2001-07-19
US6632834B2 (en) 2003-10-14
MY133571A (en) 2007-11-30
TWI246918B (en) 2006-01-11
CY1106272T1 (el) 2011-10-12
EP1120114A3 (en) 2003-08-20
US20040092506A1 (en) 2004-05-13
EP1120114A2 (en) 2001-08-01
ZA200100177B (en) 2002-07-08
CA2331053A1 (en) 2001-07-12
HU0100120D0 (en) 2001-03-28
CO5271709A1 (es) 2003-04-30
KR20010103559A (ko) 2001-11-23
AU780142B2 (en) 2005-03-03
IL140802A0 (en) 2002-02-10
HUP0100120A2 (en) 2002-10-28
JP2001213776A (ja) 2001-08-07
IL140802A (en) 2006-08-01

Similar Documents

Publication Publication Date Title
PE20011046A1 (es) Composiciones y procedimientos para el tratamiento de afecciones que responden a estrogenos
PE20011120A1 (es) Composiciones farmaceuticas de agonistas/antagonistas de estrogenos para reducir la morbilidad cardiovascular y el riesgo de mortalidad
PE20011294A1 (es) Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
PE20071254A1 (es) Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion
PE20212302A1 (es) Inhibidores de apol1 y sus metodos de uso
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
RU2011152891A (ru) Диарилгидантоины
AR004706A1 (es) Un compuesto derivado de benzoxazina y pirido-oxazina utiles como antimicrobianos, composicion farmaceutica que lo contienen, un metodo para preparar dichos compuestos e intermediarios utiles para dicho metodo.
PE20240327A1 (es) Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
PE20061303A1 (es) Composicion farmaceutica que comprende oxaprozina
CO5390047A1 (es) Derivados de uk-2a
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
MA32965B1 (fr) Derives de sulfonamides
PA8581401A1 (es) Compuestos de imedazopiridina como agonistas del receptor 5-ht4
PE20071286A1 (es) Composicion para inducir tolerancia viral en plantas
AR062965A1 (es) Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos
PE20071285A1 (es) Composicion para inducir la tolerancia de plantas contra bacteriosis
PE20030762A1 (es) Compuestos heterociclicos como antagonistas nk1
RU2007143966A (ru) Конденсированные гетероциклические соединения
AR050407A1 (es) Compuestos quinolinon-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas
CO5700719A2 (es) Derivados de alcanos azaespiro como inhibidores de las metaloproteasas
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
PE20081152A1 (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3

Legal Events

Date Code Title Description
FD Application declared void or lapsed